Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 13/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964021 | 0.88 | BCHE (0.55) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8964028 | 0.88 | BCHE (0.55) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8874474 | 0.85 | BCHE (0.56) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8874479 | 0.85 | BCHE (0.56) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8874467 | 0.85 | BCHE (0.56) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8873555 | 0.85 | MME (0.56) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8873722 | 0.85 | MME (0.56) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8875179 | 0.85 | MME (0.56) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL23780715 | 0.84 | PPARA (0.53) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8873763 | 0.84 | BCHE (0.50) | BCHEMEN1KMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595960-B1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2016-02-24 | — | — | EP | disclosed |
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | disclosed |
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD, (AU) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010843-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | REN, SUDS3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BCHE 3550/4885MEN1 2428/4885KMT2A 659/4885 |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BCHE 3624/4885MEN1 2324/4885KMT2A 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.